Welcome back,

Tag : PEDIATRIC MIGRAINE

CONFERENCE UPDATE

Fremanezumab demonstrates efficacy and safety in pediatric patients with episodic migraine: Results from the phase 3 SPACE study
The phase 3 SPACE trial found that fremanezumab significantly decreases episodic migraine frequency in children aged 6 to 17, with notable reductions in monthly migraine days (MMDs) and headache severity compared to placebo.